These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 31257354)

  • 1. Rapid temporal improvement of pembrolizumab-induced pneumonitis using the anti-TNF-α antibody infliximab.
    Sawai Y; Katsuya Y; Shinozaki-Ushiku A; Iwasaki A; Fukayama M; Watanabe K; Nagase T
    Drug Discov Ther; 2019 Jul; 13(3):164-167. PubMed ID: 31257354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Successful treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis with triple combination therapy: a case report.
    Utsumi H; Araya J; Okuda K; Watanabe J; Takekoshi D; Fujita Y; Hashimoto M; Wakui H; Minagawa S; Numata T; Hara H; Kuwano K
    Cancer Immunol Immunother; 2020 Oct; 69(10):2033-2039. PubMed ID: 32415507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis.
    Shea M; Rangachari D; Hallowell RW; Hollie NI; Costa DB; VanderLaan PA
    Cancer Treat Res Commun; 2018; 15():17-20. PubMed ID: 30207283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab.
    Ortega Sanchez G; Jahn K; Savic S; Zippelius A; Läubli H
    J Immunother Cancer; 2018 Sep; 6(1):85. PubMed ID: 30176946
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes.
    Balaji A; Hsu M; Lin CT; Feliciano J; Marrone K; Brahmer JR; Forde PM; Hann C; Zheng L; Lee V; Illei PB; Danoff SK; Suresh K; Naidoo J
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Immune-related pneumonitis caused by programmed death-1 inhibitor Pembrolizumab: a case report and literature review].
    Chen YL; Zhao J; Jia R; Wang HY; Zheng J; Bai CQ; Wang MZ; Xu JM
    Zhonghua Jie He He Hu Xi Za Zhi; 2017 Oct; 40(10):736-743. PubMed ID: 29050127
    [No Abstract]   [Full Text] [Related]  

  • 7. Nintedanib allows retreatment with atezolizumab of combined non-small cell lung cancer/idiopathic pulmonary fibrosis after atezolizumab-induced pneumonitis: a case report.
    Yamakawa H; Oba T; Ohta H; Tsukahara Y; Kida G; Tsumiyama E; Nishizawa T; Kawabe R; Sato S; Akasaka K; Amano M; Kuwano K; Matsushima H
    BMC Pulm Med; 2019 Aug; 19(1):156. PubMed ID: 31438923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dramatic, significant metabolic response to a one-time pembrolizumab treatment following a relapse of pre-existing organizing pneumonia in a patient with advanced non-small cell lung cancer: A case report.
    Kato M; Mori M; Miura K; Asao T; Motomura H; Nishino K; Ko R; Koyama R; Hayashi T; Takahashi K
    Thorac Cancer; 2021 Nov; 12(22):3076-3079. PubMed ID: 34617405
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe pneumonitis refractory to steroids following anti-PD-1 immunotherapy.
    Andruska N; Mahapatra L; Hebbard C; Patel P; Paul V
    BMJ Case Rep; 2018 Oct; 2018():. PubMed ID: 30301729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients.
    Smith DA; Radzinsky E; Tirumani SH; Guler E; Petraszko A; Kikano E; Hoimes CJ; Ramaiya NH
    AJR Am J Roentgenol; 2021 Sep; 217(3):613-622. PubMed ID: 33295801
    [No Abstract]   [Full Text] [Related]  

  • 11. A potential mechanism of the onset of immune-related pneumonitis triggered by anti-PD-1 treatment in a patient with advanced adenocarcinoma lung cancer: case report.
    Feng Y; Chen C; Zhao L; Zhu X; Zhu X; Li Q
    BMC Pulm Med; 2021 Sep; 21(1):291. PubMed ID: 34521373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A false alarm of COVID-19 pneumonia in lung cancer with anti-PD-1 related pneumonitis: a case report and review of the literature.
    Dai Y; Liu S; Zhang Y; Li X; Zhao Z; Liu P; Du Y
    J Med Case Rep; 2021 Feb; 15(1):41. PubMed ID: 33522942
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early presentation of pembrolizumab-associated pneumonitis.
    Christy J; Rafae A; Kandah E; Kunadi A
    BMJ Case Rep; 2021 Jul; 14(7):. PubMed ID: 34266820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and Histopathologic Features of Immune Checkpoint Inhibitor-related Pneumonitis.
    Larsen BT; Chae JM; Dixit AS; Hartman TE; Peikert T; Roden AC
    Am J Surg Pathol; 2019 Oct; 43(10):1331-1340. PubMed ID: 31162288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report.
    Sugano T; Seike M; Funasaka Y; Yoshida M; Takayama R; Okamura K; Nakanishi A; Tanaka T; Takeuchi S; Noro R; Minegishi Y; Kubota K; Saeki H; Gemma A
    J Immunother Cancer; 2019 Feb; 7(1):59. PubMed ID: 30813943
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement in recurring nivolumab-induced pneumonitis with repetitive administration of infliximab in a patient with head and neck cancer: A case report.
    Ueno S; Uenomachi M; Kusaba H; Ito M; Suzuki K; Ohmura H; Tsuchihashi K; Ariyama H; Akashi K; Baba E
    Mol Clin Oncol; 2021 Oct; 15(4):221. PubMed ID: 34476105
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pneumonitis: a serious adverse effect of PD-L1 inhibitors including pembrolizumab.
    Rickard F; Hyams C; Low AT
    BMJ Case Rep; 2018 May; 2018():. PubMed ID: 29735504
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pembrolizumab-Induced Seronegative Arthritis and Fasciitis in a Patient with Lung Adenocarcinoma.
    Kobak S
    Curr Drug Saf; 2019; 14(3):225-229. PubMed ID: 31132977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [No hair loss, but colitis or pneumonitis: unique side effects of immune checkpoint inhibitors for cancer].
    Steenbruggen TG; van den Heuvel MM; Blank CU; van Dieren JM; Haanen JB; Kok M
    Ned Tijdschr Geneeskd; 2016; 160():A9873. PubMed ID: 27438388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-PD-1 Inhibitor-Related Pneumonitis in Non-Small Cell Lung Cancer.
    Nishino M; Chambers ES; Chong CR; Ramaiya NH; Gray SW; Marcoux JP; Hatabu H; Jänne PA; Hodi FS; Awad MM
    Cancer Immunol Res; 2016 Apr; 4(4):289-93. PubMed ID: 26865455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.